Skip to main content

Validation of the NCI colorectal cancer risk assessment tool in the CSP 380 veterans cohort.

Publication ,  Conference
Musselwhite, LW; Redding, TS; Sims, KJ; O'Leary, M; Hauser, ER; Hyslop, T; Lieberman, DA; Provenzale, DT
Published in: Journal of Clinical Oncology
May 20, 2017

e15135 Background: Refining screening to colorectal cancer (CRC) risk may promote screening effectiveness. We applied the National Cancer Institute (NCI) CRC Risk Assessment Tool to estimate 5- and 10-year CRC risk in an average-risk Veterans cohort undergoing screening colonoscopy with follow-up. Methods: This was a prospective evaluation of predicted to actual risk of CRC using the NCI CRC Risk Assessment Tool in male Veterans undergoing screening colonoscopy with a median follow-up of 10 years.Family, medical, dietary and physical activity histories were collected at enrollment and used to calculate absolute 5- and 10-year CRC risk, and to compare tertiles of expected to observed CRC risk. Sensitivity analyses were performed. Results: For 2,934 male Veterans with complete data (average age 62.4 years, 15% minorities), 1.3% (N=30) and 1.7% (N=50) were diagnosed with CRC within 5 and 10 years of survey completion. The area under the curve for predicting CRC was 0.69 (95% CI; 0.61-0.78) at 5 years and 0.67 (95% CI, 0.59-0.75) at 10 years. We calculated the sensitivity (0.60, 95% CI; 0.45-0.73), specificity (0.67, 95% CI; 0.65-0.69) positive predictive value (0.031, 95% CI; 0.02-0.04) and negative predictive value (0.99, 95% CI; 0.98-0.99). Conclusions: The NCI CRC Risk Assessment Tool was well-calibrated at 5 years and overestimated CRC risk at 10 years, had modest discriminatory function, and a high NPV in a cohort of ethnically diverse male Veterans. This tool reliably excludes 10-year CRC in low-scoring individuals and may inform patient-provider decision making when the benefit of screening is uncertain. [Table: see text]

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2017

Volume

35

Issue

15_suppl

Start / End Page

e15135 / e15135

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Musselwhite, L. W., Redding, T. S., Sims, K. J., O’Leary, M., Hauser, E. R., Hyslop, T., … Provenzale, D. T. (2017). Validation of the NCI colorectal cancer risk assessment tool in the CSP 380 veterans cohort. In Journal of Clinical Oncology (Vol. 35, pp. e15135–e15135). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2017.35.15_suppl.e15135
Musselwhite, Laura W., Thomas S. Redding, Kellie J. Sims, Meghan O’Leary, Elizabeth R. Hauser, Terry Hyslop, David A. Lieberman, and Dawn T. Provenzale. “Validation of the NCI colorectal cancer risk assessment tool in the CSP 380 veterans cohort.” In Journal of Clinical Oncology, 35:e15135–e15135. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e15135.
Musselwhite LW, Redding TS, Sims KJ, O’Leary M, Hauser ER, Hyslop T, et al. Validation of the NCI colorectal cancer risk assessment tool in the CSP 380 veterans cohort. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017. p. e15135–e15135.
Musselwhite, Laura W., et al. “Validation of the NCI colorectal cancer risk assessment tool in the CSP 380 veterans cohort.Journal of Clinical Oncology, vol. 35, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2017, pp. e15135–e15135. Crossref, doi:10.1200/jco.2017.35.15_suppl.e15135.
Musselwhite LW, Redding TS, Sims KJ, O’Leary M, Hauser ER, Hyslop T, Lieberman DA, Provenzale DT. Validation of the NCI colorectal cancer risk assessment tool in the CSP 380 veterans cohort. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017. p. e15135–e15135.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2017

Volume

35

Issue

15_suppl

Start / End Page

e15135 / e15135

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences